The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis
Abstract
OBJECTIVE: To test the hypothesis that mycophenolate mofetil (MMF) with prednisone provides better control of myasthenic weakness than prednisone alone in the initial management of generalized myasthenia gravis (MG). METHODS: Eighty immunosuppression naïve subjects with mild to moderate generalized, acetylcholine receptor positive MG at 13 centers were randomized to 2.5 g/day MMF plus 20 mg/day prednisone (n = 41) or placebo plus 20 mg/day prednisone (n = 39) and followed in a double-blind fashion for 12 weeks. Subjects over 18 years of age were included if judged to be candidates for immunosuppression; excluded were those with thymoma or severe oropharyngeal or respiratory muscle weakness. The primary measure of efficacy was change in the quantitative MG (QMG) score from baseline to week 12. Study completers could take open-label MMF for an additional 24 weeks, while prednisone was reduced to the minimally effective dosage. RESULTS: The mean change in QMG score was similar in the treated (-4.4 +/- 5.1) and placebo (-3.6 +/- 5.0) groups (p = 0.71). The dosage of prednisone was reduced by a similar amount in both groups during the open-label phase. Subjects tolerated the study drug well, without unexpected adverse events. CONCLUSIONS: This study demonstrated no benefit of mycophenolate mofetil (MMF) with 20 mg/day prednisone compared to 20 mg/day of prednisone alone after 12 weeks. This may be due to greater than predicted benefit from the prednisone dosage used, the short duration of the study, or the absence of any benefit of MMF in this population of patients with myasthenia gravis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Introduction to sample size determination and power analysis for clinical trials
Lachin, J. M. (1981) · Controlled Clinical Trials · doi:10.1016/0197-2456(81)90001-5 · Cited by 1,012
Cited by
Myasthenia gravis: subgroup classification and therapeutic strategies
Gilhus, N. E., & Verschuuren, J. J. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00145-3 · Cited by 1,267
Gilhus, N. E. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1602678 · Cited by 1,048
Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity
Meriggioli, M. N., & Sanders, D. B. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70063-8 · Cited by 894
Howard, J. F., Utsugisawa, K., Benatar, M., Murai, H., Barohn, R. J., Illa, I., Jacob, S., Vissing, J., Burns, T. M., Kissel, J. T., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30369-1 · Cited by 845
Treatment of Neuromyelitis Optica With Mycophenolate Mofetil: Retrospective Analysis of 24 Patients
Jacob, A., Matiello, M., Weinshenker, B. G., Wingerchuk, D. M., Lucchinetti, C., Shuster, E., Carter, J., Keegan, B. M., Kantarci, O. H., & Pittock, S. J. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.175 · Cited by 308
Metadata
- Authors
- The Muscle Study Group
- Venue
- Neurology
- Published
- 2008-08-05
- Volume
- 71
- Issue
- 6
- Pages
- 394-399
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W4250520649
- Cited by
- 225
- References
- 1
- FWCI
- 10.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. https://app.cochat.ai/papers/10.1212/01.wnl.0000312373.67493.7f
- The paper
- The Muscle Study Group. (2008). A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology. https://doi.org/10.1212/01.wnl.0000312373.67493.7f
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.